Clinical Response and Improvement of the Quality of Life, Fatigue, Mood, and Sleep Disturbances During Vedolizumab Induction Therapy in Polish Patients With Moderate‐to‐Severe Ulcerative Colitis or Crohn’s Disease
Canadian Journal of Gastroenterology and Hepatology · 2026-01 · 2026 (1)
DOI: 10.1155/cjgh/9955621 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Canadian Journal of Gastroenterology and Hepatology, online erschienen am 02.06.2026. Verfasst von Agata Michalak und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology With Endoscopic Unit, Medical University of Lublin, Lublin, Poland, umlub.pl. Hauptthemen laut MEDLINE: Quality of Life, Crohn Disease, Antibodies, Monoclonal, Humanized, Colitis, Ulcerative. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company, Hanna Kurlanda-Witek of Proper Medical.
Abstract (Originalsprache)
Background
Inflammatory bowel disease (IBD) encompasses chronic gastrointestinal disorders that significantly impact patients’ quality of life (QoL). While clinical trials support the efficacy and safety of vedolizumab, real‐world data linking its effectiveness to QoL‐related patient‐reported outcomes remain limited. This prospective observational study assessed the effects of 14‐week vedolizumab induction therapy on QoL (i.e., fatigue, mood, and sleep disturbances), clinical response, safety, and predictors of response.
Methods
A total of 257 patients with ulcerative colitis (UC; n = 205) and Crohn’s disease (CD; n = 52) received 14‐week vedolizumab induction therapy. Disease activity, QoL (assessed using the total Inflammatory Bowel Disease Questionnaire [IBDQ]), fatigue (Functional Assessment of Chronic Illness Therapy‐Fatigue [FACIT‐Fatigue]), mood and sleep disturbances (PROMIS Depression and Sleep Disturbance scales), and selected biomarkers were evaluated. Clinical response was assessed using the Mayo score for UC and Crohn’s Disease Activity Index (CDAI) score for CD.
Results
At Week 14, clinical response was observed in 82% of UC patients and 82.7% of CD patients. Median total IBDQ scores increased by 45.0 points in UC and 31.5 points in CD ( p < 0.001). Median prorated FACIT‐Fatigue scores increased by 5.0 points in both groups ( p < 0.001), while median prorated PROMIS Sleep Disturbance and Depression T‐scores decreased ( p < 0.05). Improvement in QoL was moderately correlated with clinical response ( r = 0.5). In logistic regression analysis, baseline patient characteristics indicative of advanced disease were associated with a reduced likelihood of clinical and QoL response to treatment. A total of 28 adverse events were reported, including 11 serious events and four treatment‐related events.
Conclusions
Vedolizumab reduced disease activity and led to a rapid improvement in QoL during the 14‐week induction therapy in patients with IBD. Clinical response was positively correlated with QoL improvement. Predictors of reduced response were consistent with features of advanced disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology With Endoscopic Unit, Medical University of Lublin, Lublin, Poland, umlub.pl.
- Department of Gastroenterology, Prof. Tadeusz Sokołowski's University Clinical Hospital No. 1 of the Pomeranian Medical University, Szczecin, Poland.
- Department of Internal Diseases, General Hospital, Międzychód, Poland, ghlagos.org.ng.
- Department of Digestive Tract Diseases, Medical University of Lodz, Lodz, Poland, umed.pl.
- Department of Gastroenterology, Dietetics and Internal Medicine, Poznan University Clinical Hospital, Poznan University of Medical Sciences, Poznan, Poland, ump.edu.pl.
- Department of Gastroenterology and Internal Medicine, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland.
ORCID-Profile: Agata Michalak, Iwona Zawada, Anna Deskur, Maria Kopertowska-Majchrzak, Renata Talar-Wojnarowska, Danuta Domżał-Magrowska, Piotr Eder, Kamila Stawczyk-Eder, Katarzyna Waszak, Grażyna Rydzewska-Wyszkowska, Katarzyna Maciejewska, Katarzyna Karłowicz, Anita Gąsiorowska, Aleksandra Kaczka, Łukasz Konecki, Michał Krogulecki, Aleksandra Filipiuk, Maria Kłopocka, Ariel Liebert, Marek Hartleb, Magdalena Gawron-Kiszka, Elżbieta Poniewierka, Iga Gromny, Edyta Zagórowicz, Rafał Filip, Eliza Majewska, Halina Cichoż-Lach
Förderung
- Takeda Pharmaceutical Company
- Hanna Kurlanda-Witek of Proper Medical
Zitieren
APA
Michalak, A., Zawada, I., Deskur, A., Kopertowska-Majchrzak, M., Talar-Wojnarowska, R., Domżał-Magrowska, D., Eder, P., Stawczyk-Eder, K., Waszak, K., Rydzewska-Wyszkowska, G., Maciejewska, K., Karłowicz, K., Gąsiorowska, A., Kaczka, A., Konecki, Ł., Krogulecki, M., Filipiuk, A., Kłopocka, M., Liebert, A., …, & Cichoż-Lach, H. (2026). Clinical Response and Improvement of the Quality of Life, Fatigue, Mood, and Sleep Disturbances During Vedolizumab Induction Therapy in Polish Patients With Moderate‐to‐Severe Ulcerative Colitis or Crohn’s Disease. Canadian Journal of Gastroenterology and Hepatology, 2026(1). https://doi.org/10.1155/cjgh/9955621
Vancouver
Michalak A, Zawada I, Deskur A, Kopertowska-Majchrzak M, Talar-Wojnarowska R, Domżał-Magrowska D, et al. Clinical Response and Improvement of the Quality of Life, Fatigue, Mood, and Sleep Disturbances During Vedolizumab Induction Therapy in Polish Patients With Moderate‐to‐Severe Ulcerative Colitis or Crohn’s Disease. Canadian Journal of Gastroenterology and Hepatology. 2026;2026(1). doi:10.1155/cjgh/9955621
BibTeX
@article{Michalak2026,
author = {Michalak, Agata and Zawada, Iwona and Deskur, Anna and Kopertowska-Majchrzak, Maria and Talar-Wojnarowska, Renata and Domżał-Magrowska, Danuta and Eder, Piotr and Stawczyk-Eder, Kamila and Waszak, Katarzyna and Rydzewska-Wyszkowska, Grażyna and Maciejewska, Katarzyna and Karłowicz, Katarzyna and Gąsiorowska, Anita and Kaczka, Aleksandra and Konecki, Łukasz and Krogulecki, Michał and Filipiuk, Aleksandra and Kłopocka, Maria and Liebert, Ariel and Hartleb, Marek and Gawron-Kiszka, Magdalena and Poniewierka, Elżbieta and Gromny, Iga and Zagórowicz, Edyta and Filip, Rafał and Majewska, Eliza and Cichoż-Lach, Halina},
title = {Clinical Response and Improvement of the Quality of Life, Fatigue, Mood, and Sleep Disturbances During Vedolizumab Induction Therapy in Polish Patients With Moderate‐to‐Severe Ulcerative Colitis or Crohn’s Disease},
journal = {Canadian Journal of Gastroenterology and Hepatology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/cjgh/9955621}
}
EUVIMED